Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2008) 15 P78

SFEBES2008 Poster Presentations Clinical practice/governance and case reports (86 abstracts)

Zoledronate associated severe hypocalcaemia causing bradyarrhythmia that required urgent cardiac pacing

Ashref Bdiri , James Lawrence , A Jones & Martin Smith


Salisbury District Hospital, Salisbury, Wiltshire, UK.


A 71-year-old man with carcinoma of prostate and bony metastasis, presented with acute bradyarrhythmia, severe hypocalcaemia and acute renal failure 72 h after intravenous infusion of zoledronate. Before therapy, serum calcium was 2.14 mmol/l (normal, 2.10–2.55 mmol/l), serum phosphate 1.4 mmol/l (normal, 0.8–1.5 mmol/l), serum creatinine 95 umol/l and eGFR 74 ml/min. 25OH vitamin D was not measured. Three days later he presented with a syncopal episode. Initial blood pressure was 100/60 and cardiac monitoring showed nodal escape rhythm (35/min) with prolonged episodes of sinus arrest necessitating urgent cardiac pacing. His albumin-corrected serum calcium was 1.3 mmol/l, phosphate 1.29 mmol/l, 25-hydroxyvitamin D 9.5 ng/ml (normal, 20–60 ng/ml), magnesium 0.9 mmol/l (normal, 0.70–0.90 mmol/l), potassium 5.8 mmol/l, parathyroid hormone 23 pmol/l (normal, 1.5–6.0 pmol/l) and creatinine 214 μmol/l.

He required 2 weeks of continuous intravenous calcium gluconate. For the first 10 days he required 120 ml of 10% solution per day with 1 μg of 1αcalcidol to maintain a serum calcium above 1.70 mmol/l. Within 3 days of commencing calcium and vitamin D replacement, normal sinus rhythm and renal function were restored.

Zoledronate is a long-acting bisphosphonate that inhibits osteoclast-mediated bone resorption and thereby reduces serum calcium concentration. Severe acute hypocalcaemia is rarely reported and acute bradyarrhythmia necessitating urgent cardiac pacing complicating severe hypocalcaemia has not been reported.

Vitamin D deficiency has been well documented in elderly and inpatient populations and may have an incidence as high as 60%. Undiagnosed deficiency would increase the risk of acute hypocalcaemia subsequent to zoledronate and we suggest that serum calcium and vitamin D concentrations should be measured before initiating treatment. After treatment, serum calcium concentration should be monitored so that replacement therapy can be initiated as early as possible and symptomatic hypocalcaemia prevented.

Article tools

My recent searches

No recent searches.